Infectious Diseases (all articles) | Page 74 of 298 | Links Medicus Content Curation & Alerts in Medicine

Vaccines reduce the risk of long COVID by lowering the chances of contracting COVID-19. But studies suggest that vaccination might only halve the risk of long COVID, or have no effect on it at all, in a breakthrough infection. Read the @Nature report. https://t.co/MEkzXyO7hD

— Nature Portfolio (@NaturePortfolio) November 25, 2021

Cuba’s bet on home-grown COVID vaccines is paying off.

25 Nov, 2021 | 10:39h | UTC

Cuba’s bet on home-grown COVID vaccines is paying off – Nature

A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

WHO releases HIV drug resistance report 2021.

25 Nov, 2021 | 10:36h | UTC

News Release: WHO releases HIV drug resistance report 2021 – World Health Organization

Report: HIV drug resistance report 2021 – World Health Organization

Fact Sheet: HIV Drug Resistance – World Health Organization

Commentary on Twitter

🆕 Check out WHO’s latest HIV Drug Resistance Report & find out:

💊 how drug resistance is growing
💊 steps countries are taking to ensure people will receive effective medicine to treat & prevent HIVhttps://t.co/76teEHFrVV

— World Health Organization (WHO) (@WHO) November 24, 2021

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

24 Nov, 2021 | 08:51h | UTC

News Release: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Guideline: Living guidance for clinical management of COVID-19 – World Health Organziation

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinion from thirty two ministers of health: The world must act now to be prepared for future health emergencies.

24 Nov, 2021 | 08:49h | UTC

The world must act now to be prepared for future health emergencies – The BMJ

Viewpoint | Strengthening global health security and reforming the international health regulations: making the world safer from future pandemics.

Perspective | Learning from crisis: building resilient systems to combat future pandemics.

Systematic review: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics.

Opinion | The future of pandemic preparedness: agile coordination around clinical trials.

UN Report: Preventing the Next Pandemic – Zoonotic Diseases and How to Break the Chain of Transmission

Commentary on Twitter

Solidarity is key to protect the world from pandemics. This call by over 30 governments for a #PandemicTreaty to prepare for & respond to pandemics shows collaboration at work. The upcoming #WHASpecial session is a historic opportunity to make the world safer. https://t.co/98TgPce03t

— Tedros Adhanom Ghebreyesus (@DrTedros) November 23, 2021

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.

24 Nov, 2021 | 08:47h | UTC

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA – The Lancet

Review: COVID-19-associated Invasive Fungal Infection.

24 Nov, 2021 | 08:48h | UTC

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

Commentary on Twitter

A new article in OFID reviews COVID-19-associated fungal infections and addresses gaps in knowledge relating to the epidemiology, diagnosis and management of these infections: https://t.co/JIkkW70zHI #IDSAJournals #OpenForumInfectDis @PaulSaxMD @DrJLi @jobadd @DrPappasID pic.twitter.com/bPmFdKkjmb

— IDSA (@IDSAInfo) November 21, 2021

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break.

24 Nov, 2021 | 08:44h | UTC

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break – The Conversation

[Preprint] Systematic Review: Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease – “effectiveness against COVID-19 severe disease remained high (>70%) in most studies in the six months after full vaccination, although it did decrease some (on average, 8-10 percentage points) between one and six months after full vaccination”.

23 Nov, 2021 | 08:57h | UTC

Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression – Preprints with The Lancet – SSRN

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Systematic Review: Vaccines for preventing rotavirus diarrhea.

24 Nov, 2021 | 08:20h | UTC

Vaccines for preventing rotavirus diarrhoea: vaccines in use – Cochrane Library

Summary: Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? – Cochrane Library

Commentary: Vaccines for preventing rotavirus diarrhoea: an updated Cochrane review – Cochrane Library

Populational study in France did not show an increased incidence of acute myocardial infarction, stroke, and pulmonary embolism following the Pfizer vaccine.

23 Nov, 2021 | 08:51h | UTC

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older – JAMA

Scientists mystified, wary, as Africa avoids COVID disaster.

23 Nov, 2021 | 08:47h | UTC

Scientists mystified, wary, as Africa avoids COVID disaster – Associated Press

M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.

23 Nov, 2021 | 08:55h | UTC

News release: Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death – BMJ

Original Study: Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials – RMD Open

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

The COVID-19 Patient in the Surgical Intensive Care Unit.

23 Nov, 2021 | 08:46h | UTC

The COVID-19 Patient in the Surgical Intensive Care Unit – Surgical Clinics of North America

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

23 Nov, 2021 | 08:45h | UTC

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections – Infectious Diseases Society of America

Commentary on Twitter

IDSA has released NEW guidance on treating infections caused by three of the most common drug-resistant pathogens:

• AmpC-E
• CRAB
• S. maltophilia

Guidelines: https://t.co/gjxEZcxtmy
Press release: https://t.co/ulorKCmvQ4 #IDSAGuidelines #WAAW21 pic.twitter.com/Wy7uBaq2DN

— IDSA (@IDSAInfo) November 22, 2021

Antibiotic Awareness: a round-up of Cochrane evidence.

23 Nov, 2021 | 08:23h | UTC

Antibiotic Awareness: a round-up of Cochrane evidence – Cochrane Library

Commentary on Twitter

https://t.co/oVkKaj433K

@CochraneUK – excellent resources and collection of antibiotic evidence review. #tldr
Azithro doesn’t work for COVID; procalcitonin reduces antibiotic use effectively; short course durations have similar outcomes to long; & so much more

— Susan Hopkins (@SMHopkins) November 21, 2021

Review: Prevention of emerging infections in children.

23 Nov, 2021 | 08:17h | UTC

Prevention of Emerging Infections in Children – Pediatric Clinics of North America

United States FDA clears COVID vaccine boosters for all adults over 18 – Pfizer & Moderna 6 months after second jab.

21 Nov, 2021 | 23:17h | UTC

United States FDA Clears COVID Vaccine Boosters for All Adults Over 18 – Pfizer & Moderna 6 Months After Second Jab – Health Policy Watch

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

21 Nov, 2021 | 23:14h | UTC

Management of post-acute COVID-19 patients in geriatric rehabilitation: EuGMS guidance – European Geriatric Medicine

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Recent updates in antimicrobial stewardship in outpatient parenteral antimicrobial therapy.

23 Nov, 2021 | 08:15h | UTC

Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy – Current Infectious Disease Reports

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

21 Nov, 2021 | 23:15h | UTC

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Personal View—Non-invasive respiratory support in the management of acute #COVID19 #pneumonia: considerations for clinical practice and priorities for research

From Prof Hugh Montgomery & colleagues https://t.co/LLEFz2VLFu pic.twitter.com/owgAjLX5Z6

— The Lancet Respiratory Medicine (@LancetRespirMed) November 10, 2021

Stay Updated in Your Specialty